U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H32O3
Molecular Weight 344.4877
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEDRYSONE

SMILES

[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)CC[C@]34C

InChI

InChIKey=GZENKSODFLBBHQ-ILSZZQPISA-N
InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H32O3
Molecular Weight 344.4877
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Medrysone is a synthetic glucocorticoid used to to treat inflammatory eye diseases such as allergic conjunctivitis, vernal conjunctivitis, and episcleritis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HMS

Approved Use

HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone.

Launch Date

1969
Primary
HMS

Approved Use

HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone.

Launch Date

1969
Primary
HMS

Approved Use

HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone.

Launch Date

1969
Doses

Doses

DosePopulationAdverse events​
1 drop 12 times / day multiple, ophthalmic
Dose: 1 drop, 12 times / day
Route: ophthalmic
Route: multiple
Dose: 1 drop, 12 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Disc. AE: Redness of eyelid, Swelling of eyelid...
AEs leading to
discontinuation/dose reduction:
Redness of eyelid (1 patient)
Swelling of eyelid (1 patient)
Itching eyes (severe, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness of eyelid 1 patient
Disc. AE
1 drop 12 times / day multiple, ophthalmic
Dose: 1 drop, 12 times / day
Route: ophthalmic
Route: multiple
Dose: 1 drop, 12 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Swelling of eyelid 1 patient
Disc. AE
1 drop 12 times / day multiple, ophthalmic
Dose: 1 drop, 12 times / day
Route: ophthalmic
Route: multiple
Dose: 1 drop, 12 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Itching eyes severe, 1 patient
Disc. AE
1 drop 12 times / day multiple, ophthalmic
Dose: 1 drop, 12 times / day
Route: ophthalmic
Route: multiple
Dose: 1 drop, 12 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
Behavioral and neurochemical effects on rat offspring after prenatal exposure to ethanol.
2005 Jul-Aug
[Effects of electroacupuncture of Sanyinjiao (SP 6) on genito-endocrine in patients with perimenopausal syndrome].
2007 Aug
Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma.
2010 May
Patents

Patents

Sample Use Guides

One drop of medrysone eye drops should be instilled into the conjunctival sac up to every four hours.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:00:49 GMT 2023
Edited
by admin
on Sat Dec 16 16:00:49 GMT 2023
Record UNII
D2UFC189XF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEDRYSONE
INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
MEDRYSONE [MI]
Common Name English
MEDRYSONE [VANDF]
Common Name English
MEDRYSONE [ORANGE BOOK]
Common Name English
NSC-63278
Code English
U-8471
Code English
MEDRYSONE [USAN]
Common Name English
MEDRYSONE [MART.]
Common Name English
medrysone [INN]
Common Name English
11β-Hydroxy-6α-methylpregn-4-ene-3,20-dione
Systematic Name English
Medrysone [WHO-DD]
Common Name English
PREGN-4-ENE-3,20-DIONE, 11-HYDROXY-6-METHYL-, (6.ALPHA.,11.BETA.)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
NDF-RT N0000175450
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
WHO-VATC QS01BA08
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
NDF-RT N0000175576
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
WHO-ATC S01BA08
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
Code System Code Type Description
DRUG CENTRAL
1662
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID6045371
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
SMS_ID
100000081994
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201173
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
DAILYMED
D2UFC189XF
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
ECHA (EC/EINECS)
220-208-7
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
NCI_THESAURUS
C47598
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
PUBCHEM
247839
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
MESH
C100283
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
CAS
2668-66-8
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
IUPHAR
7086
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
EVMPD
SUB08701MIG
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
INN
2039
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
MERCK INDEX
m7135
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY Merck Index
FDA UNII
D2UFC189XF
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
NSC
63278
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
RXCUI
29439
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
MEDRYSONE
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
DRUG BANK
DB00253
Created by admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY